A cost-utility analysis of different antiviral medicine regimens in patients with chronic hepatitis C virus genotype 1 infection

Alavian, S. M., Nikfar, S., Kebriaeezadeh, A., Lotfi, F., Sanati, E., Rezaei Hemami, M. and Keshavarz, K. (2016) A cost-utility analysis of different antiviral medicine regimens in patients with chronic hepatitis C virus genotype 1 infection. Iranian Red Crescent Medical Journal, 18(11), e37094. (doi: 10.5812/ircmj.37094) (PMID:28203449) (PMCID:PMC5295467)

[img]
Preview
Text
137761.pdf - Published Version
Available under License Creative Commons Attribution Non-commercial.

775kB

Abstract

Background: Despite the introduction of new drug regimens with high effectiveness for the hepatitis C virus (HCV) patients, especially in HCV genotype 1, no cost-effectiveness study on the selection of the superior drug strategy in Iran has been conducted yet. Objectives: This study is aimed to assess the cost-effectiveness of the three drug regimens of pegylated interferon and ribavirin (PR), sofosbuvir (SOF) + PR and ledipasvir and sofosbuvir (LDV/SOF) in patients with HCV genotype 1 in Iran in the year 2014. Methods: A Markov micro-simulation model was used to evaluate the cost-effectiveness of the three drug strategies for a cohort of 10000 patients. Quality-adjusted life-years (QALYs) were extracted from published studies. Cost data was estimated through the review of medical records and obtaining experts opinion. Results: The results showed that the SOF + PR drug compared with PR had a lower cost and was more effective, but compared with the LDV/SOF, in spite of its lower cost, it was less efficient. The QALY values obtained for PR, SOF + PR and LDV/SOF, respectively, were 10.98, 12.08 and 12.28 and their costs were $ 41,741, $ 7,676 and $ 46,993. Moreover, the results obtained from acceptability curves showed that SOF + PR were the most cost-effective treatment for thresholds below $ 45,270 PPP. Conclusions: The use of SOF + PR regimen or LDV/SOF can significantly reduce the incidence of complications associated with the disease. For example, short and long-term outcomes are better than the current drug regimens for HCV genotype 1 patients in all stages of the disease.

Item Type:Articles
Additional Information:The study was supported by Baqiyatallah research center for gastroenterology and liver diseases, Baqiyatallah University of Medical Sciences, Tehran, IR Iran.
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Rezaeihemami, Dr Mohsen
Authors: Alavian, S. M., Nikfar, S., Kebriaeezadeh, A., Lotfi, F., Sanati, E., Rezaei Hemami, M., and Keshavarz, K.
College/School:College of Medical Veterinary and Life Sciences > School of Health & Wellbeing > Health Economics and Health Technology Assessment
Journal Name:Iranian Red Crescent Medical Journal
Publisher:Iranian Red Crescent Society
ISSN:2074-1804
ISSN (Online):2074-1812
Published Online:02 October 2016
Copyright Holders:Copyright © 2016 Iranian Red Crescent Medical Journal
First Published:First published in Iranian Red Crescent Medical Journal 18(11): e37094
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record